Akebia Therapeutics Inc
Akebia Therapeutics Inc (AKBA) Expected Move
AKBA expected move through Nov 20, 2026 is 95.7%, with 4 days to expiration. The implied range is $0.02 to $0.92, based on the previous trading day's options prices.
Read more
Tracking the AKBA expected move helps you see how far Akebia Therapeutics Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Akebia Therapeutics Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the AKBA expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For AKBA, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The AKBA expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Akebia Therapeutics Inc is unlikely to go.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the AKBA expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Akebia Therapeutics Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about AKBA.
AKBA Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Nov 20, 2026 | 4 | $0.45 | 95.7% | $0.92 | $0.02 |
| Dec 18, 2026 | 32 | $0.49 | 103.7% | $0.96 | -$0.02 |
| Jan 15, 2027 | 60 | $0.78 | 164.9% | $1.25 | -$0.31 |
| Apr 16, 2027 | 151 | $0.56 | 119.7% | $1.03 | -$0.09 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →